| Stage | ABBV | % of rev | AVGO | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $17.0B | 100.00% | $29.6B | 100.00% | AVGO ×1.74 |
| Gross profit | $12.4B | 73.03% | $20.5B | 69.13% | ABBV +3.9pp |
| Operating income | $6.4B | 37.86% | $16.0B | 53.92% | AVGO +16.1pp |
| Pre-tax income | $4.3B | 25.18% | $15.3B | 51.62% | AVGO +26.4pp |
| Net income | $3.6B | 21.28% | $13.1B | 44.23% | AVGO +22.9pp |
| Stage | ABBV | AVGO | Gap · A − B |
|---|---|---|---|
| Revenue | $17.0B100.00% | $29.6B100.00% | AVGO ×1.74 |
| Gross profit | 73.03%$12.4B | 69.13%$20.5B | ABBV +3.9pp |
| Operating income | 37.86%$6.4B | 53.92%$16.0B | AVGO +16.1pp |
| Pre-tax income | 25.18%$4.3B | 51.62%$15.3B | AVGO +26.4pp |
| Net income |
| 21.28%$3.6B |
| 44.23%$13.1B |
| AVGO +22.9pp |
No shared counterparties.